

Commercial/Healthcare Exchange Step Criteria

Effective: January 1, 2021

Step Therapy Name: Phosphate Binders

Step 1 Agent(s): sevelamer carbonate 800mg

Step 2 Agent(s): sevelamer HCL 400mg, 800mg tablets, sevelamer 0.8gm, 2.4gm powder packet, lanthanum carb 500 mg tab chew, lanthanum carb 750 mg tab chew, lanthanum carb 1,000 mg tab chew

Step 3 Agent(s): Velporo 500mg chewable tablet, Renvela 800 mg tablet, Renvela 2.4 gm powder packet, Renvela 0.8 gm powder packet, Renagel 800 mg tablet, Fosrenol 750 mg powder packet, Fosrenol 1,000 mg powder pack, Fosrenol 500 mg tablet chew, Fosrenol 750 mg tablet chew, Fosrenol 1,000 mg tablet chew

Medication/Class Description:

Phosphate binders bind phosphate within the intestinal lumen, limiting absorption and decreasing serum phosphate concentrations. These agents are indicated for treatment of hyperphosphatemia: control of serum phosphorus in patients with chronic kidney disease on dialysis.

Required Medical Information:

1. Previous therapy tried/failed

Age Restrictions: N/A

Prescriber Restrictions: N/A

Coverage Duration: 12 Months

Exceptions for Stepped Medications:

Approval for Step 2 agent will be granted if:

- A. Patient has had a trial and failure of ONE Step 1 agent, defined as:
 - a. Failure to control/improve symptoms; OR
- B. Patient has intolerance to ONE Step 1 agent, defined as (but not limited to):
 - a. Allergic reaction
 - b. Adverse drug reactions

Approval for Step 3 agent will be granted if:

- A. Patient has had a trial and failure of ONE Step 1 Agent AND TWO Step 2 Agents, defined as:
 - a. Failure to control/improve symptoms; OR
- B. Patient has intolerance to ONE Step 1 Agent AND TWO Step 2 Agents, defined as (but not limited to):
 - a. Allergic reaction
 - b. Adverse drug reactions.

References:

1. Renagel [package insert]. Cambridge, MA: [Genzyme Corporation](#); December 2012.
2. Chertow GM, Burke SK, Lazarus JM, et al. Poly[allylamine hydrochloride] (Renagel): a noncalcemic phosphate binder for the treatment of hyperphosphatemia in chronic renal failure. *Am J Kidney Dis.* 1997;29(1):66-71. [PubMed](#)

3. Fosrenol (lanthanum carbonate) [prescribing information]. Wayne, PA: Shire US Inc; September 2014.

Policy Revision history

Rev #	Type of Change	Summary of Change	Sections Affected	Date
1	New Policy	New Policy	All	1/1/2021